HeartWare Drops Valtech Deal Under Shareholder Pressure; Stays Focused On VADs
This article was originally published in The Gray Sheet
The ventricular-assist device company HeartWare International announced it was terminating its September 2015 agreement to buy heart-valve repair firm Valtech on the same day it disclosed an agreement with an activist shareholder group that opposed the deal.
You may also be interested in...
The deal will make HeartWare more of a go-to firm for heart-failure specialists, executives say. It comes soon after St. Jude Medical announced its acquisition of Thoratec, another VAD-focused firm whose technology will now be sold alongside a broader set of tools for heart-failure caregivers.
According to plaintiffs in California federal court, P&G’s claims on Herbal Essences and Pantene shampoo and conditioner products about high proportions of natural-origin or naturally derived ingredients are false and/or misleading, and ISO 16128 certification does not cure the deception.
Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.